因此，在CCCG-ALL-2015、CCCG-ALL-2020多中心研究隊列、同時研究結果和最新臨床試驗結果的基礎上，開發了CCCG-ALL-2025 I/HR-B-ALL ，以進一步改善中高風險B細胞兒童急性淋巴母細胞白血病（ I/HR-B-ALL ）兒童的無事件生存期（ EFS ）、總生存期（ OS ）和生活質量（ QOL ） ，同時減少不良反應和移植
適應症：Acute Lymphoblastic Leukemia ALL、Childhood Leukemia, Acute Lymphoblastic、B Cell Acute Lymphoblastic Leukemia (B-ALL)
收案條件
納入條件
- Age older than 1 month to younger than 18 years.
- Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
- Diagnosis of B-ALL by immunophenotyping.
排除條件
- Low-risk ALL
- sIgM+
- Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.
- ALL evolved from chronic myeloid leukemia (CML).
- Down's syndrome, or major congenital or hereditary disease with organ dysfunction
- Secondary leukemia
- Known underlying congenital immunodeficiency or metabolic disease
- Congenital heart disease with cardiac insufficiency.
- Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。